Skip to content

DNA Methylation and Autoimmune Thyroid Diseases

Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02491567
Acronym
THYRODNA
Enrollment
110
Registered
2015-07-08
Start date
2014-09-30
Completion date
2018-04-30
Last updated
2019-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease, Hashimoto Thyroiditis

Brief summary

Hashimoto Thyroiditis (HT) and Graves Disease (GD) are known to be caused by abnormal immune response against self cells and tissues. Epigenetics is a novel field of biology studying the mechanisms by which the environment interacts with the genotype to produce a variety of phenotypes through modifications to chromatin that do not directly alter the DNA sequence. A very limited number of epigenetic studies have been published in patients with HT and GD so far. Therefore, the purpose of this study is to analyze DNA methylation status in White Blood Cells (WBCs) within the promoter regions of genomic sites that have been previously identified as susceptibility loci or sites for autoimmune thyroid disease, such as the CD40L, FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 genes.

Detailed description

Hashimoto Thyroiditis (HT) and Graves Disease (GD) are known to be caused by abnormal immune response against self cells and tissues. HT involves a cell-mediated autoimmune destruction of the thyroid leading to hypothyroidism. GD is caused by a process in which immune cells make stimulating antibodies against the thyroid stimulating hormone (TSH) receptor on the thyroid gland, thus leading to hyperthyroidism. Although there is substantial evidence that genetic factors increase the risk for developing autoimmune diseases, monozygotic twins still remain discordant for disease (disease concordance is never 100%), thus suggesting a role for environmental factors and epigenetics. Epigenetics is a novel field of biology studying the mechanisms by which the environment interacts with the genotype to produce a variety of phenotypes through modifications to chromatin that do not directly alter the DNA sequence. These modifications have been associated with altered gene expression and silencing of repetitive elements and can be inherited mitotically. Epigenetic mechanisms include DNA methylation, histone modifications, or miRNA post-transcriptional regulation. DNA methylation involves the covalent addition of a methyl group to the carbon-5 position in the CpG dinucleotide from the methyl donor S-adenosylmethionine and is mediated by a group of enzymes called DNA methyltransferases (DNMTs). CpG dinucleotides are typically grouped together in regions known as CGIs (islands). CGIs can be found in the promoter regions of genes, and CpG methylation of these gene promoters is associated with transcriptional silencing. In contrast, hypermethylated genes have been found to be transcriptionally active. A very limited number of epigenetic studies have been published in patients with HT and GD so far. Therefore, the purpose of this study is to analyze DNA methylation status in White Blood Cells (WBCs) within the promoter regions of genomic sites that have been previously identified as susceptibility loci or sites for autoimmune thyroid disease, such as the CD40L, FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 genes. Initially, recruitment of patients and controls as well as blood sample collection will be done. A complete physical examination will also be performed in all participants included in the study, and a detailed personal, family, gestational and perinatal history will be obtained as well before inclusion. Blood samples by all participants will be collected and centrifuged and then White Blood Cells (WBCs), plasma and serum will be separated and stored in a deep freezer. Laboratory analyses will follow. DNA will be isolated from peripheral leukocytes using the QIAamp DNA Blood Mini Kit, according to the manufacturer's instructions. It will then be treated with sodium bisulfite using the Zymo EZ DNA Methylation-Gold Kit, again according to the manufacturer's protocol. Therefore, unmethylated cytosines will be converted into uracyls, whereas methylated cytosines will remain unchanged. Quantification of the methylation status of DNA at the gene promoter regions under study will be made, using specific primers that detect modified DNA, by real-time PCR and analysis of the melting curves of the selected fragments of DNA. Amplicons will also be analyzed by electrophoresis and visualized by ultraviolet trans-illumination. An electronic Data Base will be constructed and Statistical Analysis will follow. Results and Conclusions will be published in peer-review journals and presented in International Meetings.

Interventions

None listed

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

For HT: A positive titers of antithyroid peroxidase (anti-TPO) or antithyroglobulin (anti-Tg) antibodies and at least one of: * Abnormal thyroid function that requires substitution treatment with L-thyroxine (TSH \> 5 μIU/ml and decreased or normal levels of fT4 or fT3) * Increased volume of thyroid gland (goiter) * Morphological changes on ultrasound of the thyroid gland For GD: * A positive titers of thyroid stimulating antibodies (anti-TSI) and * Decreased TSH levels and increased levels of fT4 or fT3 For Controls: * Otherwise healthy children and adolescents, age- and gender-matched with patients * Absence of previously known chronic disease of autoimmune aetiology or atopy (including those with a history of chronic treatment with antihistamines, anti-inflammatory, corticosteroids or anti-epileptic drugs) * Absence of a family history of autoimmune disease in first-degree relatives

Exclusion criteria

* Not Caucasian origin or affinity among participants * Age of diagnosis above 18 years * Disease duration below 3 months

Design outcomes

Primary

MeasureTime frameDescription
DNA methylation status of CpGs within gene promoters1 monthPercentage of DNA methylation of CpGs within the CD40L, FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 promoter genes in White Blood Cells (WBCs).

Secondary

MeasureTime frameDescription
Duration of breastfeeding1 dayDuration of breastfeeding until discontinuance
History of phototherapy1 dayHistory of phototherapy during neonatal period (or not)
APGAR score1 dayAPGAR score at 1st and 5th min of life
Age1 dayAge of each participant
Age of disease onset1 dayAge of disease diagnosis
Sex1 dayMale or female
Body mass index1 dayWeight in kg / height in m \* height in m
Pubertal stage1 dayPrepubertal or pubertal stage
Antibodies titre1 dayTitre of antiTPO, antiTg, anti-TSI antibodies in blood
Thyroid volume1 dayVolume of the thyroid gland in total (both lobes)
Treatment dose1 dayDose of Levothyroxine/thiamazole per kg of body weight /per day (if applicable)
B121 dayLevels of B12 in blood
Folic acid1 dayLevels of folic acid in blood
IgA, IgG, IgM, IgE immunoglobulins1 dayLevels of IgA, IgG, IgM, IgE immunoglobulins in blood
History of infections1 dayNumber of previous febrile viral /bacterial infections per year
History of medications1 dayNumber of previous medications per year
Other autoimmune diseases1 dayDiagnosis of co-existing autoimmune disease (except autoimmune thyroid disease)
Family history of autoimmune thyroid (or other) disease1 dayFamily history of autoimmune thyroid (or other) disease or not
Parental educational level1 dayElementary school, high school or university graduate
Type of Residence1 dayUrban or rural residence
Parental smoking1 dayTotal number of cigarettes per day during their child's life separately for each parent (if applicable)
Previous births1 dayNumber of previous births
Month of birth1 dayMonth of birth (from January to December)
Delivery type1 dayCesarean section or vaginal delivery
Birth weight1 dayBirth weight
Gestation duration1 dayDuration of pregnancy
Medications during pregnancy1 dayNumber of medications of any type received during pregnancy (if applicable)
Maternal smoking during pregnancy1 dayTotal number of cigarettes per day during pregnancy (if applicable)
Maternal alcohol consumption during pregnancy1 dayTotal number of glasses of alcohol consumption per day during pregnancy (if applicable)
Pre-eclampsia (during pregnancy)1 dayDiagnosis of pre-eclampsia (during pregnancy) or not
Gestational diabetes (during pregnancy)1 dayDiagnosis of gestational diabetes (during pregnancy) or not
Vaginal bleeding (during pregnancy)1 dayPresence of vaginal bleeding (during pregnancy) or not
Maternal febrile infection (during pregnancy)1 dayDiagnosis of maternal febrile infection (during pregnancy) or not

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026